In 2015, the haematologist Jay Bradner made the leap from supervising a few dozen researchers in his lab at the Dana-Farber Cancer Institute to overseeing more than 6,000 scientists at Novartis. As president of the Novartis Institutes for BioMedical Research (NIBR), he has now rolled out his vision for NIBR 2.0 — with an increased focus on chemical biology and open science. He spoke with Asher Mullard about his plans to restructure around emerging drug discovery tools and to forge closer ties with the rest of the scientific community.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Journal of Translational Medicine Open Access 08 May 2018
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
18 April 2017
Two typographical errors that may have affected the meaning of the answers related to the creation of the Chemical Biology & Therapeutics unit within NIBR and the focus of the NIBR leadership on open science have been corrected.
Rights and permissions
About this article
Cite this article
Jay Bradner. Nat Rev Drug Discov 16, 232–233 (2017). https://doi.org/10.1038/nrd.2017.50
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.50
This article is cited by
-
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Journal of Translational Medicine (2018)
-
Erratum: An audience with Jay Bradner
Nature Reviews Drug Discovery (2017)
